A Multicenter, Open-Label, Randomized Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis
Latest Information Update: 07 Jun 2024
At a glance
- Drugs Bimekizumab (Primary)
- Indications Plaque psoriasis
- Focus Pharmacokinetics
- Acronyms BE CONNECTED
- Sponsors UCB Biopharma
- 22 Feb 2024 Planned End Date changed from 3 Apr 2025 to 19 Mar 2025.
- 22 Feb 2024 Planned primary completion date changed from 3 Apr 2025 to 19 Mar 2025.
- 19 Aug 2022 Planned End Date changed from 1 Mar 2025 to 3 Apr 2025.